Table 1.

Clinicopathologic characteristics of HD patients

A. HD patients with second tumor
Gender
    Female: 6
    Male: 4
Mean age at diagnosis
    30 y (range 14-42)
Histologic type
    Lymphocyte-predominant: 1
    Nodular sclerosing: 6
    Lymphocyte-depleted: 2
    Mixed cellularity: 1
Stage
    I: 3
    II: 4
    III: 1
    IV: 2
Treatment:
    CT exclusive MOPP/ABVD: 2
    RT exclusive: 3
    Combined CT (4 MOPP, 1 MOPP/ABVD) + RT: 5
Relapse:
    3 (RT+CT-MOPP, 2 and RT + ABVD, 1)
Average time from treatment until the second tumor:
    12.9 y (range 4-25)
Type second tumor:
    Breast cancer: 2 (1 male)
    Diffuse large B-cell lymphoma: 1
    Soft tissue sarcoma: 1
    NSCLC: 4
    GIST: 1
    Cervix carcinoma: 1
Treatment with RT on the second tumor area:
    All patients (10)
B. HD patients with no second tumor
Gender
    Female: 7
    Male: 12
Mean age at diagnosis
    36 y (range 7-72)
Histologic type
    Lymphocyte-predominant: 1
    Nodular Sclerosing: 11
    Lymphocyte-depleted: 2
    Mixed Cellularity: 5
Stage:
    I: 3
    II: 5
    III: 7
    IV: 4
Treatment:
    CT (ABVD) without RT: 11
    Other CT (MOPP):1
    RT exclusive: 3
    CT (ABVD) and RT: 4
Relapse:
    5 (CT, 4 and RT, 1)
Mean follow-up:
    12.5 y (range 6-27)

Abbreviations: MOPP, Nitrogen mustard, vincristine, procarbazine, and prednisone; ABVD, Adriamycin, bleomycin, vinblastine, and dacarbazine; RT, radiotherapy; CT, chemotherapy; NSCLC, non–small cell lung cancer; GIST, gastrointestinal stromal tumor.